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The complexity of heart failure has led to the development of guidelines seeking
to clarify or simplify diagnostic approaches and therapeutic interventions
(American College of Cardiology (ACC)/American Heart Association (AHA)
guidelines and European Society of Cardiology (ESC) — guidelines revised, as
well as South African guidelines).
1-3
Heart failure is a common disorder that affects 1 - 2% of the adult population
and more than 10% of those aged more than 65 years. For the GP, the important
factors in the management of patients with heart failure can be summarised as
follows:
• Identification of patients at risk and institution of appropriate therapeutic and
preventive measures.
• Identification of relevant symptoms and clinical features that lead to a diagno-
sis of heart failure (and being able to exclude other aetiological causes of con-
gestion/fluid overload) and institution of basic, standard treatment where appro-
priate.
• Identification of clinical features that require further diagnostic imaging tech-
niques.
• The ability to detect complications in those being followed up.
DEFINITION
There is no simple, objective definition of heart failure.  The definition by Milton
Packer is detailed and embodies all aspects of this complex syndrome: ‘Heart
failure represents a clinical syndrome characterized by abnormalities of left ven-
tricular function and neurohormonal regulation which are accompanied by effort
intolerance, fluid retention and reduced longevity.’
4
AETIOLOGY
Numerous aetiological factors lead to the development of heart failure; hence the
saying ‘Many roads lead to a broken heart’ (Fig. 1).
CLASSIFICATION
The current staging of heart failure takes cognisance of it as a progressive dis-
ease with identifiable risk factors (conditions) and serves to complement the New
York Heart Association (NYHA) classification, which is based on the severity of
symptoms (Tables I and II).
Risk factors (conditions)
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DIAGNOSIS AND TREATMENT OF
HEART FAILURE IN THE COMMUNITY 
Heart failure still remains a serious public health problem with significant morbidity
and mortality, despite significant therapeutic interventions.
The risk factors are as follows:
• hypertension
• coronary artery disease
independently or in co-existence con-
tribute to majority of heart failure cases
• diabetes mellitus
• valvular heart disease
• idiopathic dilated cardiomyopathy.
}
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GPs can play a significant role in the
identification of patients at risk of
developing heart failure as they are
often the first to see them, particularly
those with hypertension and diabetes.
Appropriate therapeutic/preventive
measures may prevent, retard or delay
progression to heart failure.
DIAGNOSIS
The diagnosis of heart failure relies on
clinical judgement based on history,
physical examination and appropriate,
relevant cost-effective investigations.
The ESC heart failure diagnostic
guidelines and the Framingham diag-
nostic criteria for heart failure are use-
ful tools in the diagnosis (Tables III and
IV).
Once a diagnosis of heart failure is
made, the underlying aetiology should
be identified and appropriate treat-




Exertional dyspnoea is the earliest and
commonest symptom; however, it is
neither specific nor restricted to heart
failure.  Other forms of dyspnoea, i.e.
paroxysmal nocturnal dyspnoea and
orthopnoea, usually indicate advanced
stages of heart failure (however, these
are also not specific for heart failure).
Fatigue
Fatigue is nonspecific and non-diag-
nostic, but may be useful when inter-
preted in the context of other symp-
toms.
Poor effort tolerance
Poor effect tolerance is also 
nonspecific.
Ankle oedema
This is a common presenting feature,
but it is nonspecific and becomes help-
ful in the diagnosis of heart failure in
men rather than in women.
Clinical findings
The clinical signs are caused by con-
gestion and can be specific and non-
specific.5
Specific clinical findings
• Elevated jugular venous pressure.
• Gallop rhythm.
• Displaced apical impulse.
The above signs occur in severe heart
failure, which reduces their sensitivity






Comment:  None of the above symp-
toms and physical signs (even the spe-
cific ones) in isolation can be predic-
tive of heart failure.
Once a diagnosis of heart failure is
made the severity must be determined,
for which the NYHA functional classifi-
cation can be used.
Investigations
The clinical suspicion of heart failure
should be followed by supportive
diagnostic investigations.
Basic investigations
Urine analysis. This is a basic test
done on site by the GP and may give
clues to underlying renal problems
(which may result in fluid overload)
and presence of diabetes.
Basic haematology and bio-
chemistry tests. The following tests
are recommended as part of a routine
diagnostic evaluation of heart failure:
Haematology 
• full blood count 
• haemoglobin
• platelets




• urea and electrolytes
• hepatic function.
Additional tests may be required.
These will depend on whether there is
a clinical suspicion of the underlying
cause, e.g. cardiac markers in the
context of myocardial infarction.
Results from the above basic investiga-
tions may be extremely useful in deter-
mining other aetiological factors with 
regard to clinical presentation or pre-
cipitating factors (Table V).
B-type natriuretic peptide is becoming









Fig. 1. Heart failure — broad aetiological factors.
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Table I. Stages of heart failure (HF)
Description Examples
A Patients at high risk of developing HF Systemic hypertension, coronary artery disease, diabetes
because of the presence of conditions mellitus, history of cardiotoxic drug therapy or alcohol
that are strongly associated with its abuse, personal history of rheumatic fever, family
development.  Such patients have history of cardiomyopathy 
no identified structural or functional 
abnormalities of the pericardium, 
myocardium or cardiac valves and 
have never shown signs or symptoms of HF
B Patients who have developed structural Left ventricular hypertrophy or fibrosis, left ventricular
heart disease that is strongly associated dilatation or hypocontractility, asymptomatic valvular
with the development of HF but who have heart disease, previous myocardial infarction
never shown signs or symptoms of HF
C Patients who have current or prior symptoms Dyspnoea or fatigue due to left ventricular systolic
of HF associated with underlying dysfunction, asymptomatic patients under-
structural heart disease going treatment for prior symptoms of HF 
D Patients with advanced structural heart Patients who are frequently hospitalised for HF or
disease and marked symptoms of HF at rest, cannot safely be discharged from hospital;
despite maximal medical therapy, and who patients in hospital awaiting heart transplantation;
require specialised interventions patients at home receiving continuous intravenous
support for symptom relief or being supported with a 
mechanical circulatory assist device; patients in a hospice 
setting for the management of HF 
Adapted from ACC/AHA guidelines.1
Table II. New York Heart Association classification of heart failure
Class I No limitation: ordinary physical exercise does not cause undue fatigue, dyspnoea or
palpitations 
Class II Slight limitation of physical activity: comfortable at rest but ordinary activities result in fatigue, 
palpitations or dyspnoea 
Class III Marked limitation of physical activity: comfortable at rest but less than ordinary activity results 
in symptoms
Class IV Unable to carry out any physical activity without discomfort: symptoms of heart failure are 
present even at rest, with increased discomfort with any physical activity  
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heart failure. However, its role as part
of routine, clinical assessment in gener-
al practice is not yet supported by
studies.
Once such studies are available and
positive, the cost-effectiveness of this
screening tool will have to be deter-
mined.
Electrocardiogram (ECG)
An ECG is a very useful, cheap diag-
nostic tool that is available on site and
should be performed routinely in all
patients with a clinical suspicion of
heart failure.
Abnormal ECG findings may reflect the
following:
• arrhythmias — predominantly atrial,
but occasionally ventricular
• signs of previous myocardial infarc-
tion and/or ischaemia
• features of right ventricular enlarge-
ment or hypertrophy
• features of left ventricular hypertrophy
A normal ECG is unusual in heart fail-
ure and should suggest a review of the
diagnosis.2,3
Chest radiograph
Chest radiography is a relatively
cheap, easily accessible, important,
supportive diagnostic tool that should
be performed in all patients with a
clinical suspicion of heart failure.  The
following three factors need to be eval-
uated:
• Size and shape of the cardiac
shadow (this can provide important
Table III. European Society of Cardiology guidelines for the diagnosis of heart failure
Essential features
Symptoms of heart failure, e.g breathlessness, fatigue, ankle oedema 
Objective evidence of cardiac dysfunction (at rest) 
Non-essential features
In cases where the diagnosis is in doubt, there is a response to treatment directed towards heart failure 
Adapted from Heart 2000; 84: 334-338.5
Table IV. Framingham criteria for congestive heart failure






Central venous pressure >16 cm H2O
Circulation time 25 s 
Hepatojugular reflux
Pulmonary oedema, visceral congestion, or cardiomegaly at outopsy
Weight loss — 4.5 kg in 5 days in response to treatment of congestive heart failure
Minor criteria Bilateral ankle oedema
Nocturnal cough
Dyspnoea on ordinary exertion
Hepatomegaly
Pleural effusion
Decrease in vital capacity by one-third from maximal value recorded
Tachycardia (120 beats/min)
In this study the diagnosis of congestive heart failure requires that two major or one major and two minor 
criteria be present concurrently.  Minor criteria were acceptable only if they could not be attributed to another
medical condition.
Adapted from Braunwald E.  Heart Disease — A Textbook of Cardiovascular Medicine. 6th ed.
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information concerning the exact
nature of the underlying heart dis-
ease).
• Distribution of the pulmonary vascu-
lar markings and fluid in the inter-
stitial space.
• Fluid in the pleural/subpleural
space (Table VI).
Transthoracic echocardiography
This is one of the imaging methods
used objectively to assess ventricular
function.  It is also extremely useful in
identifying primary valvular abnormali-
ties and pericardial disease as aetio-
logical factors.
Ideally all patients with clinical evi-
dence of heart failure should have
echocardiographic examination, 
specifically to assess the abovemen-
tioned structural changes as part of
their initial assessment. However, in
view of lack of expertise at a primary
care physician level (GP level), coupled
with cost implication, routine echocar-
diography is not feasible.  The ques-
tion that arises is who should then be
referred for this important, non-inva-
sive examination in the initial assess-
ment of heart failure?
The South African guidelines3 suggest:
• obvious clinical diagnosis of a
heart murmur.
• clinical evidence of organic valvu-
lar heart disease, ventricular hyper-
trophy, pericardial disease and
restrictive cardiomyopathy 
• uncertain clinical diagnosis and
inconclusive radiological findings.
TREATMENT
The syndrome of heart failure requires
multiple strategies — from prevention
to advanced mechanical therapeutic
interventions.
Prevention
Risk factors (conditions) (outlined
above) predisposing to the develop-
ment of ventricular dysfunction and




• dietary measures (reduction of salt
intake, moderate alcohol intake,
fluid restriction when necessary) 
• appropriate weight loss programme
if overweight 
Table V. Haematology and biochemistry
Haemoglobin: Estimation, mean cell volume, white cell count 
Aetiology: Anaemia that is severe enough (Hct < 25%) can produce signs and symptoms of conges-
tive heart failure (CHF) without underlying cardiac abnormalities 
Differential diagnosis: Polycythaemia and a raised haematocrit suggest that breathlessness may 
be caused by lung disease, cyanotic heart disease or a pulmonary arteriovenous malformation 
Precipitating factor: Haematocrit between 25% and 35% may aggravate underlying cardiac 
disease.  A raised white cell count may prompt investigation to exclude infection 
Urea and creatinine
Differential diagnosis: Renal insufficiency or failure may cause fluid overload mimicking heart 
failure, especially if severe hypertension is the cause of the renal dysfunction.  Untreated heart failure 
is rarely associated with the major electrolyte disturbances found in renal failure 
Precipitating factor: Worsening renal function either due to the natural progression of the heart 
disease or to a side-effect of non-cardiac medication (especially NSAIDs); cardiac medication (over-
diuresis together with ACE) may precipitate a worsening in the cardiac status 
Liver function tests
Aetiology: An increase in aspartate transminase (AST) greater than that in alanine aminotransferase 
(ALT) increased gamma glutamyl transferase (GT) and alkaline phosphatase (ALP) may be found with 
alcohol abuse. A congested, ischaemic liver may show a transaminitis (ALT, AST) 
Differential diagnosis: Severe primary liver disease with hypoalbuminaemia, and deranged 
enzymes may present with a congested state not dissimilar to CHF 
Precipitating factor: Drug-related liver toxicity (e.g. amiodarone) may precipitate clinical deterioration 
Adapted from S Afr Med J 1998; 88 (9): part-2.3
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• regular exercise programme 
• appropriate counselling on compli-
ance and other issues (family
should be involved in the coun-
selling programme).
GPs can play a significant
role in the identification of
patients at risk of develop-
ing heart failure as they
are often the first to see
them, particulary those
with hypertension and dia-
betes.  Appropriate thera-
peutic/preventive measures
may prevent, retard or
delay progression to heart
failure.
Once a diagnosis of heart
failure is made, the under-
lying aetiology should be
identified and appropriate




The goal of this treatment strategy is to
relieve symptoms and improve life
expectancy; hence the use of multi-
drug therapy.
Symptomatic treatment
Diuretic treatment (loop diuretics)
is useful in patients with fluid reten-
tion.  Improvement in symptoms is
noted within a few hours to days.
Therapy should be initiated with low
doses and titrated up.
Furosemide is a commonly used diuret-
ic and is extremely cheap. Volume and
electrolyte depletion (especially K+) are
common complications of chronic
diuretic therapy. Diuretics are used in
combination with other therapeutic
agents as maintenance treatment.
Digoxin improves symptoms and
exercise tolerance in patients treated
with diuretics, ACE inhibitors and 
β−blockers.  It is also useful in heart
failure patients with atrial fibrillation.
Lower doses (i.e. 0.125 mg) are sug-
gested for use in heart failure to
reduce the toxic side-effects profile,
especially in the context of hypo-
kalaemia and hypomagnesaemia.
Major side-effects are gastrointestinal, 
neurological and conduction distur-
bances.
Therapies that improve sur-
vival
ACE inhibitors. Clinical trials have
shown that ACE inhibitor therapy sig-
nificantly improves survival in addition
to symptomatic improvement through-
out the different stages of heart failure.
Current guidelines recommend their
use as first-line therapy in conjunction
with diuretics. Therapy should be initi-
ated at low doses and titrated to maxi-
mum appropriate dosages (as used in
the clinical trials) (Table VII).
Availability of generic ACE inhibitors
has further reduced the cost of this
important therapeutic intervention in
heart failure.
Renal function and potassium levels
should be assessed within 1 - 2 weeks
of starting treatment. Important side-




ACE inhibitor therapy is contraindicat-
ed in renal artery stenosis, pregnancy
and documented angio-oedema in
cases of previous exposure to ACE
inhibitors.
Table VI. Chest radiographic findings
Syndrome: A normal cardiothoracic ratio on the posteroanterior radiograph and a normal left ventricular size
on the lateral chest radiograph make the diagnosis of CHF unlikely, urging a careful review of the clinical evi-
dence 
Cardiomegaly together with pulmonary venous congestion in symptomatic patients is highly suggestive of CHF,
although reliable interpretation of pulmonary congestion varies 
The chest radiograph should never be reviewed in isolation, as congestion of renal or neurogenic origin may
be indistinguishable from cardiac congestion 
Aetiology/differential diagnosis: The chest radiograph is also useful in helping to exclude other diag-
noses
Pulmonary disease, pericardial calcification, calcified heart valves, left atrial enlargement associated with
mitral stenosis and isolated right ventricular enlargement would all support diagnoses other than pure, chronic
left ventricular systolic dysfunction 
Precipitating factor(s): The chest radiograph helps to diagnose a correctable precipitating factor/s
— a pneumonia, or pulmonary infarct(s) that can precipitate the episode of clinical heart failure may be 
identified 
Adapted from S Afr Med J September 1998; 88 (9): part 2.3
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Table VII. ACE inhibitor dosages — from clinical trials
Agent Starting dosage Target dosage Trial
Captopril 6.25 mg tds 25 - 50 mg tds SAVE
Enalapril 5 mg bd  10 mg bd  SOLVD P/T
Lisinopril 2.5 mg daily 40 mg daily ATLAS
Ramipril 2.5 mg bd  5 mg bd  AIRE
AIRE = Acute Infarction Ramipril Efficacy; ATLAS = Assessment of Treatment with Lisinopril and Survival; SAVE = Survival and Ventricular Enlargement; SOLVD P/T =
Studies of Left Ventricular Dysfunction (Prevention/Treatment). 
Adapted from American Journal of Cardiology May 2003, Supplement on heart failure. A symposium:  from prevention to management of chronic heart failure.
Table VIII. Dosage of β-blockers used in heart failure trials
Agent Starting dosage Target dosage Trial
Bisoprolol 1.25 mg daily 10 mg daily CIBIS II
Carvedilol 3.125 mg bd  25/50 mg bd US carvedilol heart failure studies 
COPERNICUS
Metoprolol CR/XL 12.5/25 mg daily 220 mg daily MERIT-HF
CIBIS II = Cardiac Insufficiency Bisoprolol Study II;  COPERNICUS = Carvedilol Prospective Randomised Cumulative Survival
Trial; MERIT-HF = Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure.
Adapted from:  American Journal of Cardiology May 2003, Supplement on heart failure.  A symposium: from prevention to management of chronic heart failure.
Table IX. Pharmacological therapy of symptomatic chronic heart failure due to systolic left ventricular dysfunction
For symptoms For survival morbidity For symptoms if intolerance to 
ACE inhibitor or beta-blockade
NYHA Reduce/stop diuretic Continue ACE inhibitor if 
I asymptomatic.  Add beta-blocker if 
post-myocardial infarction
NYHA =/- diuretic, depen- ACE inhibitor as first-line treatment Angiotensin II receptor antag-
onist (ARB) if ACE inhibitor 
intolerant
II ding on fluid retention
Add beta-blocker if still symptomatic or ACE inhibitor + ARB if beta- 
blocker intolerant
NYHA + diuretics + digitalis 
III if still symptomatic ACE inhibitor and beta-blockade, ARB if ACE inhibitor intolerant
+ nitrates/hydralazine  add spironolactone or ACE inhibitor + ARB if
if tolerated beta-blocker intolerant
NYHA Diuretics + digitalis ARB if ACE inhibitor intolerant
IV + nitrates/hydralazine
if tolerated ACE inhibitor
+ temporary inotropic beta-blockade or ACE inhibitor + ARB if beta-
support spironolactone blocker intolerant
Adapted from the Task force report: ESC: Guidelines for the diagnosis and treatment of heart failure. Eur Heart J 2001; 22: 1527-1560.2
Beta-blockers. Clinical trials have
shown β-blockers to reduce mortality
and hospitalisation in heart failure. 
β-blocker treatment should be initiated
in patients whose heart failure has
been clinically stable for 2 - 4 weeks,
with no evidence of acute decompen-
sation or fluid overload with standard
care.6
Initiation of β-blocker therapy may
worsen myocardial performance at the
start of treatment; hence the recom-
mendation that the starting dose
should be very low and then titrated
up. For the suggested dosage see
Table VIII.
It is advisable to use the β-blockers
used in clinical trials.
Although β-blocker therapy is still rela-
tively expensive compared with other
standard drugs used in heart failure,
its benefit outweighs the cost, which
makes this therapy important for use in
heart failure.
Before initiating therapy the patient
should be screened for the following
contraindications:
• symptomatic bradycardia or
hypotension
• 2nd and 3rd degree AV block
• bronchial asthma.
Other therapies
Spironolactone. There is a strong
suggestion that this reduces mortality
and is useful with other therapeutic
agents in severe to advanced heart
failure.
Nitrates and hydralazine combi-
nation. There is no specific recom-
mendation for the standard use of this
combination in clinical practice,
except in patients intolerant of ACE
inhibitors.
Angiotensin II receptor antago-
nists. More data are required for
their use in heart failure. The current
cost of these drugs makes them prohib-
itive for widespread use in heart fail-
ure at a community level.
Mechanical and electrical thera-
peutic strategies will not be dis-
cussed here, as they are beyond the
scope of this article.
It is important to realise that patients
being treated for heart failure are like-
ly to be on other drug regimens for
treatment of concomitant medical con-
ditions, and compliance may become
a problem.  Appropriate counselling
on adherence to therapy is extremely
important if therapeutic benefits are to
be seen.
Table IX shows suggested therapies
according to the severity of symptoms.
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Coronary artery disease aetiology
NYHA class
Exercise capacity







Left ventricular ejection fraction
Right ventricular ejection fraction
Left ventricular stroke work index
Left ventricular filling pressure
Right arterial pressure
Left ventricular systolic pressure
Mean arterial pressure
Cardiac index

















Adapted from Braunwald E. Heart Disease — A Textbook of Cardiovascular Medicine. 6th ed.4
PROGNOSIS
Heart failure accounts for a substantial
portion of all cardiovascular deaths.
Fifty per cent of patients diagnosed
with heart failure die within 5 years.
Numerous factors have been found to
correlate with mortality (Table X).
WHEN TO REFER
Patients must be referred in the follow-
ing cases:
• clinical suspicion of underlying
valvular heart disease 
• severe heart failure 
• clinical evidence of left ventricular
hypertrophy 
• clinical suspicion of coronary
artery disease 
• stability followed by clinical deteri-
oration not explained by non-com-
pliance.
References available on request.
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The mortality and morbidity of heart failure remain high despite major 
therapeutic advances in the last two decades, partly because of inadequate
health care service programmes and structure as well as the under-use of
proven effective treatment (β-blockers and ACE inhibitors).
The new classification which uses the staging system is extremely useful in 
making it possible to identify the early stages (stages A and B) of heart failure,
where appropriate therapeutic intervention can prevent or delay the progres-
sion to symptomatic heart failure with irreversible left ventricular dysfunction.
A systematic approach should be followed in the diagnosis of heart failure, 
taking into account the symptomatology, clinical findings and appropriate 
cost-effective diagnostic procedures.
The GP can play a significant role by early identification of patients at risk, 
modification of the predisposing risk factors as well as early, appropriate
referral of those who may have correctable aetological factors.
IN A NUTSHELL
EVOLVED TO EAT MEAT
Contrary to what my beloved (now deceased) godmother, a convinced vegetarian, always used to tell me, humans have
evolved to eat meat. According to a study of our ancestors' teeth, we evolved into meat-eaters around 2.5 million years
ago. Analysis by an anthropologist at the University of Arkansas,  showed that the first member of Homo had much sharper
teeth than their most likely ancestor, Australopithecus afarensis — Lucy's species. Meat eating needs teeth which can cut
rather than grind, which is determined by the slope of the cusps — they must be sharply sloped. Early Homo teeth have
these sharply sloped cusps, steeper than those of gorillas that don't eat meat.
(Holtzman D. New Scientist 2003; 6 September, p.19.)
SINGLE SUTURE
